Literature DB >> 23052163

Vinorelbine-based chemo-radiotherapy in non-small cell lung cancer.

Vieri Scotti1, Calogero Saieva, Vanessa Di Cataldo, Alessio Bruni, Isacco Desideri, Silvia Bertocci, Icro Meattini, Lorenzo Livi, Gabriele Simontacchi, Carla De Luca Cardillo, Benedetta Bendinelli, Paolo Bastiani, Monica Mangoni, Benedetta Agresti, Giampaolo Biti.   

Abstract

AIMS AND
BACKGROUND: Concomitant radio-chemotherapy improves survival of patients with locally advanced non-small cell lung cancer, with a better local-regional control. METHODS AND STUDY
DESIGN: We report our experience with vinorelbine-based chemotherapy in neoadjuvant and radical settings in 43 patients. Regimens consisted of cisplatin plus vinorelbine in 74.4% patients and carboplatin plus vinorelbine in 14.0%; 11.6% underwent mono-chemotherapy with oral vinorelbine. We estimated the crude probability of death or local recurrence by the Kaplan-Meier method. Cox regression models were used to identify the main significant predictors of death or local recurrence.
RESULTS: A significant effect of the response to treatment was shown on both local disease free-survival (P = 0.004) and overall survival (P <0.0001). Patients with progressive disease after primary treatment had a significantly higher risk of further relapse at both univariate (P = 0.046) and multivariate regression analysis (P = 0.014) than patients with a complete response. They also showed a significantly higher risk of death at both univariate (P = 0.0005) and multivariate regression analysis (P <0.0001) than patients with a complete response. The most common toxicity was hematologic and gastroenteric. We recorded grade III/IV leukopenia in 11%, anemia in 6%, and esophagitis in 14% of the patients.
CONCLUSIONS: Our experience showed that vinorelbine-based chemotherapy is an effective and safe regimen, in association with a platinum compound and thoracic radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23052163     DOI: 10.1177/030089161209800411

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  2 in total

1.  Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells.

Authors:  Shirong Zhang; Kan Wu; Jianguo Feng; Zhibing Wu; Qinghua Deng; Chao Guo; Bing Xia; Jing Zhang; Haixiu Huang; Lucheng Zhu; Ke Zhang; Binghui Shen; Xufeng Chen; Shenglin Ma
Journal:  Oncotarget       Date:  2016-10-18

Review 2.  Oral vinorelbine: a feasible and safe partner for radiotherapy in the treatment of locally advanced non-small cell lung cancer.

Authors:  Francesco Perri; Grazia Lazzari; Giuseppina Della Vittoria Scarpati; Giovanni Silvano
Journal:  Onco Targets Ther       Date:  2016-04-19       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.